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ABSTRACT
Previously, we reported that a mutant of Tat referred to as Nullbasic inhibits HIV-1 reverse transcription although the mecha-
nism of action is unknown. Here we show that Nullbasic is a reverse transcriptase (RT) binding protein that targets the reverse
transcription complex rather than directly inhibiting RT activity. An interaction between Nullbasic and RT was observed by us-
ing coimmunoprecipitation and pulldown assays, and a direct interaction was measured by using a biolayer interferometry as-
say. Mixtures of recombinant 6His-RT and Nullbasic-FLAG-V5-6His at molar ratios of up to 1:20,000 did not inhibit RT ac-
tivity in standard homopolymer primer template assays. An analysis of virus made by cells that coexpressed Nullbasic showed
that Nullbasic copurified with virus particles, indicating that it was a virion protein. In addition, analysis of reverse transcription
complexes (RTCs) isolated from cells infected with wild type or Nullbasic-treated HIV-1 showed that Nullbasic reduced the lev-
els of viral DNA in RTC fractions. In addition, a shift in the distribution of viral DNA and CAp24 to less-dense non-RTC frac-
tions was observed, indicating that RTC activity fromNullbasic-treated virus was impaired. Further analysis showed that viral
cores isolated from Nullbasic-treated HIV undergo increased disassembly in vitro compared to untreated HIV-1. To our knowl-
edge, this is the first description of an antiviral protein that inhibits reverse transcription by targeting the RTC and affecting core
stability.
IMPORTANCE
HIV-1 infection is treated by using combinations of antiretroviral drugs that target independent steps of virus replication. A
newly described antiviral protein called Nullbasic can also inhibit a combination of different steps in virus replication (tran-
scription, reverse transcription, and Rev-mediated viral mRNA transport), although the precise mechanism of action is un-
known. This study shows that Nullbasic can inhibit reverse transcription by binding to the viral enzyme called reverse transcrip-
tase, which results in accelerated uncoating of the viral core and instability of the viral apparatus called the reverse transcription
complex (RTC). This unique antiviral activity may inform development of other RTC inhibitors, as well as providing a unique
investigative tool for dissecting the RTC cellular composition.
Like all retroviruses, HIV-1 has a single positive-sense strand ofRNA genome that is converted into double-strand proviral
DNA by a hallmark process called reverse transcription. Proviral
DNA is subsequently integrated into the host chromosomes and is
transcribed by RNA polymerase II producing viral mRNA. The
mechanisms regulating reverseHIV-1 transcription have been de-
scribed in detail elsewhere (1). Briefly, the viral mRNA genome
annealed to host cell tRNALys3 form a ribonucleoprotein complex
with viral proteins, including reverse transcriptase (RT), integrase
(IN), and nucleocapsid to form a prototypical reverse transcrip-
tion complex (RTC) (2). The initiation of reverse transcription by
the RTC begins shortly after cell infection after cytoplasmic nu-
cleotides become available. Using tRNALys3 as a primer, DNA syn-
thesis by RT produces a short strand of DNA called negative-
strand strong stop DNA (sssDNA). Degradation of the viral
RNA strand by RT RNase H activity liberates sssDNA that is
transferred to the 3= end of the viral RNA by annealing of comple-
mentary nucleotide sequences, a step called first-strand transfer.
The synthesis of the remaining negative-strand DNA can then be
completed by RT. The complete synthesis of double-strand pro-
viral DNA follows additional DNA synthesis following additional
priming reactions and strand displacement DNA synthesis by RT.
Cellular factors, including eEF1A, associate with the RTC and play
an important role in the reverse transcription process (3, 4).
Many virion proteins, including Tat, affect the efficiency of
reverse transcription. Tat is an HIV-1 regulatory protein with
pleiotropic effects on various cellular and viral functions. As ex-
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amples, Tat stimulatesHIV-1 gene expression through interaction
with a cellular transcription factor called pTEFb, composed of
cyclin T1 and CDK9, and histone deacetylases (5). Tat regulates at
least two steps ofHIV-1mRNAprocessing, including cotranscrip-
tional capping by Mce1 (6) and mRNA splicing through interac-
tions with p32, an ASF/SF-2 splicing cofactor (5). Harrich et al.
demonstrated that native Tat stimulated HIV-1 reverse transcrip-
tion (7), andApolloni et al. showed that Tat improved the binding
of reverse transcriptase to the RNA template, which required in-
tact Tat activation and basic domains (8), although a precise role
for Tat in reverse transcription has been controversial (9).
Previously, we described a mutant of the two-exon HIV-1 Tat
protein, termed Nullbasic, which can potently inhibit multiple
steps of the HIV replication cycle (10). Nullbasic was created by
replacing the entire arginine-rich basic domain of wild-type Tat
with glycine/alanine residues. Given that Tat has reported ability
to enhance HIV-1 reverse transcription (7, 8, 11, 12), is present in
HIV-1 virions (13), and can interact with reverse transcriptase (8),
we performed experiments to determinewhethermutant forms of
Tat could antagonize this Tat function.We showed that Nullbasic
did strongly inhibited HIV-1 reverse transcription (10, 14), but,
unexpectedly, Nullbasic effectively decreased the steady-state lev-
els of unspliced and singly spliced viral mRNA, an activity caused
by inhibition of HIV Rev (10, 15). Both human T cell lines and
primary human CD4 cells constitutively expressing Nullbasic
were protected from a spreading infection byHIV-1 (14), indicat-
ing that Nullbasic is a potent HIV-1 inhibitor. Very few single
antiviral agents that block HIV replication at multiple steps of the
life cycle have been described (16).
Like some related one-exon Tat mutants (17, 18), Nullbasic
exhibited trans-dominant negative (TDN) effects on Tat-depen-
dent HIV gene expression (10). TDN inhibitors (TDNi) are de-
fined as a mutant proteins that lack an intrinsic activity that can
inhibit function of the wild-type protein in trans (19). Early stud-
ies showed that Tat TDNi inhibited HIV-1 trans-activation of
transcription if expressed in excess compared towild-type Tat (17,
18). The proposed mechanism of Tat TDNi inhibition of HIV-1
transcription involves sequestration of the cellular protein com-
plex PTEF-b (18, 20). Tat TDNi can interact with PTEF-b but due
to mutation of the basic domain cannot bind HIV-1 TAR RNA
(21), which is necessary for hyperphosphorylation of the RNA
polymerase II C-terminal domain by PTEF-b, leading to efficient
transcriptional elongation. Subsequent studies showed that first-
generationTat TDNimodestly protected humanT cells lines from
HIV-1 replication (22), and coexpression of a Tat and Rev TDN
(RevM10) inhibited HIV-1 infection and replication better than
individual expression (22), presumably by additive or multiplica-
tive effect due to inhibiting two steps of virus replication. RevM10
is a competitive inhibitorwild-typeRev (23) that bindsCRM1 and
inhibits export of Rev-mRNA complexes from the nucleus (24).
We showed that coexpression of Nullbasic and Rev caused a
CRM1-dependent change of Rev localization in cells and defective
Rev function (10, 15).
Nullbasic can also inhibit HIV-1 reverse transcription that sig-
nificantly diminishes infectivity of HIV-1, as well virus-like parti-
cles (VLPs) of lentiviral vector systems typically based on HIV-1
made by cells expressing Nullbasic (10, 14). Nullbasic inhibits
HIV-1 and VLP infectivity 4- to 10-fold in a dose-dependent
manner. Defective HIV-1 and VLP infection caused by Nullbasic
has been observed in different target cells, including primary hu-
man CD4 lymphocytes, Jurkat, HeLa, TZM-bl, and HEK293T
cells (10, 14).With respect to early replication, the affected HIV-1
or VLPs are defective for synthesis of the first product of reverse
transcription called negative-strand strong stopDNA (sssDNA)
as determined by monitoring endogenous reverse transcription
reactions and viral DNA synthesis following cell infection (10, 14).
While Nullbasic affects HIV-1 andHIV-1-based VLPs, it does not
affect murine leukemia virus based retroviral vectors indicating
that Nullbasic is a specific HIV-1 inhibitor (14). Whether this is
due to direct or indirect effects of Nullbasic on RT, the RTC or
another mechanism has not been determined.
In this study, we further investigated how Nullbasic inhibits
reverse transcription. We show here that Nullbasic can directly
bind HIV-1 RT. Although this does not appear to downregulate
RT activity in a standard in vitro RT assay, our experiments indi-
cate that Nullbasic affects viral core disassembly, leading to defec-
tive viral DNA synthesis by the reverse transcription complex. To
our knowledge, this makes Nullbasic a protein inhibitor of the
reverse transcription with a novel mechanism of action.
MATERIALS AND METHODS
Cell lines and HIV-1NL4.3. HEK293T cell lines were grown in Dulbecco
modified Eagle medium supplemented with 10% heat-inactivated new-
born bovine serum, penicillin-streptomycin 50 to 100 IU/ml. All cells
were incubated at 37°C in 5% CO2 incubator. A stock of HIV-1NL4.3was
generated as previously described (3) by transfection of the corresponding
proviral DNA using X-tremeGENEHPDNA transfection reagent (Roche
Applied Science) into HEK293T cells according to the manufacturer’s
recommendations. Cell culture supernatants were removed at 48 h post-
transfection and centrifuged (200 g, 10 min), and the supernatant was
filtered (0.45-m pore size) and stored in 1-ml aliquots at80°C.
Plasmids. For expression of HIV RT subunits p51and p66 in cells, the
coding DNA sequences were amplified from pHGPsyn (25), which con-
tains a Gag/Pol codon-optimized sequence, and the PCR fragment was
inserted into pDONR vector using Gateway system (Invitrogen) by BP
recombination reaction. The inserts were then transferred into destina-
tion mammalian expression vectors that contain a V5 tag by LR recombi-
nation reactions. The pCDNA3.1-Nullbasic-FLAG and pCDNA3.1-Null-
basic-FLAG-mCherry expression plasmids were previously described (10,
15). ANullbasic-FLAGDNA fragment lacking a stop codonwas produced
by PCR using the Gateway system and inserted into pDEST42. The
plasmid pDEST42-Nullbasic-FLAG was used to make recombinant Null-
basic-FLAG-V5-6His protein in Escherichia coli. To make the
pGCHENV plasmid, the pGCH plasmid (10, 15) was digested with
BamHI and SalI to make a vector. A corresponding BamHI and SalI DNA
fragment was obtained from the plasmid pNL4-3.Luc.R.E (NIH AIDS
Reagent Program catalog number 3418) and ligated into the pGCH
vector.
Recombinant proteins. The recombinant RT protein was kindly pro-
vided by Stuart Le Grice (HIV Drug Resistance Program, Center for Can-
cer Research, National Cancer Institute). The recombinant Nullbasic-
FLAG-V5-6His was produced in E. coli strain BL21-AI (Invitrogen)
transformed by pDEST42-Nullbasic-FLAG plasmid. A 200-ml culture
was grown in Luria broth to log phase and induced with 0.2% arabinose
and 1 mM IPTG (isopropyl--D-thiogalactopyranoside). After 4 h, the E.
coli was collected by centrifugation and immediately processed. First, 1
FastBreak cell lysis reagent (Promega) was added to the cell pellet for 15
min, and the lysate was mixed with 2 ml of HisLink protein purification
resin (Promega) for 1min. The beads were placed into a column and 6ml
of wash buffer (100 mMHEPES [pH 7.5], 10 mM imidazole) was applied
six times. Then, 2ml of elution buffer (100mMHEPES [pH 7.5], 500mM
imidazole) was added and collected after 1 min. The eluted protein was
dialyzed twice for 90 min each in 1 liter of storage buffer (20% glycerol
[vol/vol], 50 mM Tris-HCl [pH 8.0], and 1 mM ZnSO4, adding fresh 2
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mM1,4-dithioerythritol every 30min). The proteinwas stored in aliquots
in liquid nitrogen.
Coimmunoprecipitation (co-IP), pull-down, and Western blot
analyses. HEK293T cells were transfected with each plasmid alone or in
combination as shown. The cells were lysed at 48 h posttransfection in
S100 buffer (10 mM Tris [pH 7.4], 1.5 mM MgCl2, 10 mM KCl, 1
complete protease inhibitor cocktail [Roche Applied Science], 0.5 mM
-mercaptoethanol) using aDounce homogenizer. The lysate was cleared
by centrifugation in a refrigerated microcentrifuge at 4°C and 13,500 g
for 30 min. The supernatant (500 l) was incubated with 10 l of anti-
FLAG antibody coated beads (Sigma, IL) for 2 h at 4°C. The immunopre-
cipitate was washed twice with S100 buffer plus 0.01 to 0.02% Triton
X-100, followed by Western blot analysis with anti-Tat or anti-RT anti-
bodies. For the pulldown experiment, FLAG-beads were saturated with
recombinant Nullbasic-FLAG-V5-6His protein and washed with 1
phosphate-buffered saline (PBS) to remove unbound protein. The loaded
beads were incubated with 500 l of RTp51 and RTp66 lysates. As a
control, a lysate containing RTp51 and RTp66 were incubated with un-
bound FLAG-beads. Otherwise, pulldown assays were performed as de-
scribed for the co-IP assays.
Biolayer interferometry (BLI) assay. RT (50 g) was biotinylated
using EZ-Link Sulfo-NHS-Biotin according to the manufacturer’s in-
structions (Pierce Biotechnology, IL). To immobilize the biotinylated
protein onto biosensors, biosensors coupling with streptavidin (Pall
ForteBio, CA) were incubated in the biotinylated protein at a final con-
centration of 1 M for 15 min in 1 kinetic buffer using the OctetRed
system (Pall ForteBio). The association of the two proteins was measured
by incubating ligand biosensors (biotinylated protein) into another pro-
tein solution (analyte, nonbiotinylated) with shaking at 1,000 rpm. The
concentration of analytes Nullbasic-FLAG-V5-6His and bovine serum
albumin (BSA) ranged from 270 nM to 10 nM in 3-fold serial dilutions.
The dissociation was determined by moving the ligand biosensor from
analyte to the kinetic buffer only. The kinetic buffer (1mMphosphate, 15
mMNaCl, 0.002%Tween 20, 1.5Mgelatin) was used in all experiments.
The data were analyzed using the ForteBio data analysis program (Pall
ForteBio), and a mean kd and ka for each protein-protein interaction was
calculated from three independent experiments, where Kd	 kd/ka. A chi-
squared test, least-squares fit analysis was determined by the using Forte-
Bio data analysis program.
RT assay. The RT assay (Roche Applied Science) was performed ac-
cording to the manufacturer’s instructions with exceptions. Protein mix-
tures containing recombinant HIV-1 RT heterodimer at 1.5 nM and re-
combinant Nullbasic-FLAG-V5-6His at 3 nM, 30 nM, 300 nM, and 3
M in 1 PBS (pH 7.5) were incubated at room temperature for 30 min.
A separate sample included the RT inhibitor nevirapine used at a final
concentration of 200 nM. The remaining reaction components provided
by the manufacturer were added, and the samples were incubated at 37°C
for 10 min. The DNA products were processed according to the protocol
provided.
Immunofluorescence microscopy. HEK293T cells (0.5  106) were
grown on glass coverslips in six-well plates and transfected with 1 g of
Nullbasic-FLAG-mCherry plasmid using X-tremeGENE HP DNA trans-
fection reagent according to the manufacturer’s instructions. After 24 h,
the cells were fixed in 3% (wt/vol) paraformaldehyde at room tempera-
ture for 10 min and quenched with 50 mM NH4Cl for 5 min. The cells
were then permeabilized with 0.1% (vol/vol) Triton X-100 for 15 min.
Nuclei were stained with 1 M DAPI (4=,6=-diamidino-2-phenylindole;
Life Technologies). Finally, the coverslips were mounted onto slides with
ProLong Gold antifade reagent (Life Technologies). Fluorescent images
were captured using a Leica TCS SP2 confocal scanningmicroscope (Leica
Microsystems) with 63 objective lenses and standard lasers and filters
for mCherry and DAPI fluorescence.
Purification of HIV-1 particles by velocity gradients.HEK293T cells
were cotransfected with 5 g of pGCH proviral plasmid and 3.3 g of
pcDNA3.1/Nullbasic-FLAG or pcDNA3.1 plasmid. Cell culture superna-
tants were harvested 48 h after transfection and filtered through 0.45-m-
pore-size filters. Viruses in supernatants were concentrated by ultracen-
trifugation through a 20% (vol/vol) sucrose cushion at 125,000 g for 1
h. The pellet was washed with 1 PBS and resuspended in 500 l of PBS
overnight at 4°C. The concentrated viral particles were further purified by
velocity gradient ultracentrifugation usingOptiprep (Axis-Shield) diluted
from6 to 18%as described previously (26). Gradient fractions (1ml)were
collected from the top of the tube and assayed for p24 antigen using the
RETROtek HIV-1 p24 antigen enzyme-linked immunosorbent assay
(ELISA) (Zeptometrix Corp.). The purified virions in each gradient
fraction were concentrated again by ultracentrifugation and subjected
to Western blot analysis. Nullbasic-FLAG protein was detected using a
rabbit anti-DYKDDDDK Tag polyclonal antibody (Cell Signaling
Technology).
Subtilisin analysis. The subtilisin assay used was adapted from a pub-
lished method (27). Briefly HIV-1 was concentrated by ultracentrifuga-
tion through 20% sucrose at 125,000  g for 1 h at 4°C. The pellet was
resuspended in PBS at a ratio of 1:100. Concentrated virus preparation
was added to an equal volumeof subtilisin digestion buffer at a ratio of 1:1,
followed by incubation at 37°C for 2 h. The enzymatic reaction was
stopped by the addition of 5g of phenylmethylsulfonyl fluoride/ml. The
digested virions were pelleted through another 20% sucrose cushion by
ultracentrifugation as previously described. The pelleted samples were
solubilized in 2 sodium dodecyl sulfate (SDS) loading dye and used in
Western blot assays with an anti-HIVIG (NIH AIDS Reagent Program),
anti-CA (Santa Cruz), anti-MA (Santa Cruz), andM2 anti-FLAG (Sigma)
antibodies and the appropriate secondary antibody conjugated to horse-
radish peroxidase (HRP).
RTC purification. Purification of HIV RTC has been described previ-
ously (28). Briefly, VSV-G envelope-pseudotyped HIV-1 was produced
by cotransfecting HEK293T cells in a 10-cm dish that were 70% confluent
with 5 g of pGCHENV proviral plasmid, 2 g of pCMV-VSV-G plas-
mid, and 3.3 g of pcDNA3.1/Nullbasic-FLAG or pcDNA3.1 using X-
tremeGENE HP DNA transfection reagent according to the manufactur-
er’s instructions. At 48 h posttransfection, supernatants containing
viruses were harvested, filtered through 0.45-m-pore-size filters, and
treatedwithDNase I for 30min at 37°C. Viral CAp24 concentrations were
determined by ELISA. HEK293T cells were grown in a T-175 flask until
they were 80% confluent and then incubated with HIV-1 supernatant
having 5 g of CAp24 or the same amount of heat-inactivated HIV-1
using Polybrene (8 g/ml) at 4°C for 2 h and then at 37°C for 4 h. Cell
lysates prepared as previously described (3) were placed on top of a linear
sucrose gradient (20 to 70% [wt/wt]) and subjected to centrifugation at
145,000 g for 18 h at 4°C. Then, 1-ml fractions were collected from the
bottom of tube and assayed by qPCR for HIV-1 sssDNA as previously
described (29) using 0.2-l portions of each fraction. The CAp24 concen-
trations in each fraction were assayed by ELISA.
HIV-1 entry assay. HEK293 cells grown in 10-cm dishes until 80%
confluent were treated with 1 M nevirapine (NVP) for 2 h at 37°C and
then incubated with VSV-G-pseudotyped HIV-1 or HIV-1-Nullbasic vi-
ral supernatant containing 500 ng of CA for 2 h at 4°C to facilitate virus
attachment. The cells were incubated at 37°C to initiate envelope and cell
membrane fusion and then incubated for a further 2 h. Each sample was
collected using TRIzol reagent (Life Technologies), and the RNA fraction
was column purified using a Direct-Zol miniprep kit (Zymo Research)
and treated on the column with DNase I prior to elution. The purified
RNAs were used in RT-PCRs in the presence or absence of SuperScript III
reverse transcriptase (Life Technologies) using randomhexamer oligonu-
cleotides for the first-strand DNA synthesis. Second-strand DNA and
PCR was performed using oligonucleotides specific for full-length viral
mRNA as previously described (10). All samples were used in qPCRs to
measure eEF1A mRNA using the oligonucleotides 5=-CTGGAGCCAAG
TGTCTAATATGCC (forward) and 5=-GCCAGGCTTGAGAACACC
AGTC (reverse). A plasmid containing EEF1A1 was used to generate a
standard curve. A Rotor-Gene 600 was used for DNA amplification at
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95°C for 15 s and annealing and elongation at 60°C for 1 min. A negative
control without cDNA template was included in every assay.
In vitro core stability assay. HIV-1 cores were purified as previously
described with minor modification (30). Briefly, high titer HIV-1 de-
scribed above was pelleted by ultracentrifugation at 125,000  g for 1 h
through 20% sucrose and resuspended in 1PBS–1mMEDTAovernight
at 4°C. The virus particles underwent a “spin-thru” detergent treatment as
previously described (30) in a 30 to 70% sucrose in 1 PBS–1mMEDTA
buffer. Gradients were formed using a Biocomp gradient master (Bio-
Comp Instruments, Inc.). The gradients were fractionated from the bot-
tom of the gradient collecting 1-ml fractions. Fractions containing CA
with a density of 1.24 to 1.27 were used in in vitro uncoating assays as
previously described (30) using a Beckman TLA100.3 rotor.
Electron microscopy analysis. HEK293T cells were cotransfected
with 2g of pGCH proviral plasmid and 1.7g of pCDNA3.1/Nullbasic-
FLAG or pcDNA3.1 plasmid. At 48 h posttransfection, the cells were fixed
with 5% (vol/vol) glutaraldehyde (ElectronMicroscopy Sciences) at room
temperature for 2 h. Fixed cells were contrasted with 1% osmium tetrox-
ide and 4%uranyl acetate prior to dehydration and embedding in LX-112
resin (31). Sections (60 nm) were cut using an ultramicrotome (UC64;
Leica), and viral particles were visualized at60,000 using a transmission
electronmicroscope (model 1011; JEOL) equipped with aMorada cooled
charge-coupled device camera and iTEM AnalySIS software. Three sam-
ples of Nullbasic-treated and untreated cells were inspected collecting sets
of 60 to 160 images of virus particle from each independent sample. An
unpaired Student t test was used to calculate P values.
RESULTS
Nullbasic directly interactswithRT.Wepreviously reported that
the HIV-1 Tat protein could associate with RT (8), suggesting the
possibility that Nullbasic (10), a mutant of Tat, may also interact
with RT. To test this possibility, co-IP experiments were under-
taken using plasmids expressing carboxyl-FLAG epitope tagged
Nullbasic and plasmids expressing codon-optimized reverse
transcriptase p66 and p51 genes each having carboxyl-6His and
V5 epitope tags (25). HEK293T cells were transfected with each
plasmid alone or in combination as shown (Fig. 1A). After 48 h,
lysates were prepared, and Nullbasic was immunoprecipitated
with anti-FLAGantibody-coated beads.Weobserved that RT sub-
units, RT p66 and p51, expressed separately were coimmunopre-
cipitated, indicating that Nullbasic could associate with either RT
subunit. Pulldown experiments performed in parallel using re-
combinant Nullbasic-FLAG-V5-6His protein purified from E.
coli (shown in Fig. 1C) also showed that Nullbasic could associate
with each RT subunit (Fig. 1B, lanes 6 and 7). Neither RT subunit
bound to the anti-FLAG beads in the absence of Nullbasic (Fig. 1
lane 4). These experiments indicate that Nullbasic can associate
with RT p66 and p51 subunits in vitro.
Next, using theOctet Red96 system, BLI was used to determine
whether protein association between recombinant Nullbasic (Fig.
1C) and RT was direct. A streptavidin-coated biosensor was satu-
rated with biotinylated RT, incubated with Nullbasic-FLAG-V5-
6His or BSA protein in a range of 10 to 270 nM, and subse-
quently immersed in disassociation buffer. The biosensor
sensograms were recorded using Octet Red96 system. The senso-
grams clearly showed that Nullbasic bound to immobilized re-
combinant RT under these experimental conditions (Fig. 2A).
The kinetic interactions between Nullbasic-FLAG-V5-6His and
an RT heterodimer probe showed that interaction was satisfacto-
rily fitted by a 1:1 bindingmodel. The goodness of the fitted curves
was indicated by a low apparent 
2 of 1.87, where values of 10
are considered acceptable (32). The calculated Kd of the interac-
tion was 40 nM under the conditions tested. No binding be-
tween the RT probe and BSA was detected, indicating that the
interaction between RT and Nullbasic was specific (Fig. 2B). The
BLI data supported the results obtained by co-IP and pulldown
experiments and further indicated that the interaction between
RT and Nullbasic is direct.
Recombinant Nullbasic does not affect RT activity in vitro.
We undertook in vitro experiments to address whether Nullbasic
inhibited RT activity in a standard in vitro HIV-1 RT assay. The
FIG 1 Co-IP of RT subunits with Nullbasic. HEK293T cells were transfected
with plasmids that can express RT subunits p51 (RT p51) and p66 (RT p66).
The RT subunits have carboxy-terminal 6His and V5 epitope tags. (A) As
indicated for lanes 1 to 7, a plasmid expressing Nullbasic-FLAG (NB) was
transfected alone or in combination with an RT expression plasmid(s). Cell
lysates were made from transfected cells, and 20 g of total protein was ana-
lyzed by SDS-PAGE and Western blotting with rabbit anti-RT or anti-Tat
antibody. (B) In lanes 1 to 5, immunoprecipitation reactions were performed
with 100g of total protein, and beads coatedwith amouse anti-FLAGmono-
clonal antibody were incubated at 4°C for 2 h. In lanes 6 and 7, pull-down
reactions were performed with 100 g of total protein, and beads coated with
recombinant Nullbasic-FLAG-6His protein were incubated at 4°C for 2 h.
The captured protein underwent SDS-PAGE and Western blot analysis with
the same anti-RT and anti-Tat antibodies. The results of a representative ex-
periment of four experiments that all had similar results are shown. (C) Null-
basic-FLAG-V5-6His proteinwas purified from E. coli. Approximately 50 ng
of Nullbasic was applied to a SDS–10% PAGE gel and stained with Coomassie
blue (left panel). A parallel lane on the same gel that underwent Western blot
analysis with a rabbit anti-Tat antibody is shown (right panel).
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assay uses a homopolymer RNA template and oligonucleotide
primer as a substrate for DNA synthesis by RT. RT (1.5 nM) was
mixedwith sameNullbasic-FLAG-V5-6His used in previous ex-
periments (Fig. 1C) or BSA at molar ratios of 1:2, 1:20, 1:200,
1:2,000, and 1:20,000 for 30 min at room temperature prior to
addition to the RT assay. The assays were incubated at 37°C for 10
min, and the amount of DNAmade was compared to DNA levels
made by standard concentrations of RT run in parallel. The results
showed no significant inhibition of RT activity in the presence of
Nullbasic or BSA at the concentrations tested (Fig. 3). As a control,
side by side assays were incubated with nevirapine at 200 nM that
produced no detectable DNA (data not shown). The results indi-
cate that recombinant Nullbasic does not directly inhibit RT ac-
tivity in vitro in a standard assay.
Nullbasic is present in HIV-1 particles. Confocal imaging of
Nullbasic-FLAG-mCherry fusion proteins show that they are dif-
fusely distributed in the cytoplasm and nucleus when expressed in
humanHeLa cells (10, 15) andHEK293T cells (Fig. 4A). It seemed
possible that Nullbasic could be packaged in virions during bud-
ding given its wide distribution in the cytoplasm, its proximity to
the cell plasma membrane, and its interaction with RT. Also,
HIV-1 made by cells expressing Nullbasic are defective in endog-
enous reverse transcription reactions and in reverse transcription
after cell infection compared to HIV-1 made by untreated cells
(10, 14). To test this possibility, we made HIV-1 in cells by
cotransfection of pGCH, a proviral HIV-1 expression plasmid,
and a Nullbasic-FLAG expression plasmid. The virus particles
were purified using iodixanol velocity gradients that separate
HIV-1 from contaminating cellular microvesicles (26). Virus in
supernatants were pelleted through 20% sucrose, resuspended in
1 PBS and placed onto a 6 to 18% iodixanol velocity gradient.
Fractions collected from the top of the gradient were assayed for
CA by ELISA (Fig. 4) and for the presence of Nullbasic-FLAG by
Western blotting. The elution profile for capsid was similar for
HIV-1 irrespective of whether the virus producing cell expressed
Nullbasic (Fig. 4). It was observed that Nullbasic was detected in
the same fractions that contained peak CA in fractions 4 and 5
consistent with its incorporation in virus particles.
We performed subtilisin treatment to confirm that Nullbasic
was present in virus particles. As shown in Fig. 5, coexpression of
Nullbasic and HIV-1 by cells produced particles that copelleted
with Nullbasic after passing through a 20% sucrose cushion (Fig.
5A, lane 2). Nullbasic was not detected in control HIV-1 (Fig. 5A,
lane 1). Western blot analysis of HIV-1 treated with subtilisin
showed significant reduction in levels of gp120 compared to un-
treated HIV-1 (Fig. 5B and C, top panels), but the levels of CA or
MA were similar, confirming that subtilisin did not degrade pro-
teinswithin virus particles. Nullbasicwas also detected in the same
Western blot, indicating that Nullbasic was inside virus particles
and thus protected from subtilisin digestion. The combined ex-
periments indicate that expression of Nullbasic in HIV-1-infected
cells results in the incorporation ofNullbasic inside virus particles.
ViralDNAassociationwith theRTC is reduced byNullbasic.
Since recombinant Nullbasic had no effect on RT activity in vitro
(Fig. 3) but can downregulatesssDNA synthesis during reverse
transcription in ERT assays and in cells (10, 14), we examined
whether Nullbasic affected DNA synthesis by changing of the
composition or the activity of RTCs. The RTCswere isolated from
HIV-1-infected cells by using equilibrium density centrifugation,
as previously described (3, 28, 33). VSV-G envelope-pseudotyped
HIV-1 made in cells in the presence or absence of Nullbasic was
FIG2 BLI sensograms of binding events betweenNullbasic andRT. TheOctet
Red96 system was used to measure binding events between Nullbasic and RT.
(A andB) BLI sensograms. BiotinylatedRTp51/66was bound to a streptavidin
biosensor and applied to solutions containing 10 nM (green), 30 nM (light
blue), 90 nM (red), or 270 nM (dark blue) of Nullbasic-FLAG-V5-6His (A)
or (B) BSA. The BLI experiment was repeated at three times with similar
results. The results of a representative sensogram are shown.
FIG 3 Nullbasic does not inhibit RT enzymatic activity in vitro. HIV-1 RTwas
preincubated with Nullbasic or BSA for 30 min at room temperature, as indi-
cated. The remaining reaction components were added to the proteinmixture,
followed by incubation for 10 min at 37°C. The reverse transcription DNA
products were measured according to the manufacturer’s instructions. The
experimentwas performed in triplicate and repeated three times. The results of
a representative experiment are shown.Mean values and standards error of the
mean are shown.
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used to synchronously infect HEK293T cells. Cells incubated with
equivalent amounts of heat-inactivated HIV-1 were used as neg-
ative controls for the experiment. The cells were incubated for 4 h,
and cytoplasmic lysates prepared from the infected cells were frac-
tionated using a 20 to 70% linear sucrose gradient and equilibrium
density centrifugation. Fractions collected from the bottom of the
gradient were assayed for HIV-1 sssDNA by qPCR and for CA
by ELISA (Fig. 6). The viral RTC, which has a density of 1.32 to
1.34 g/ml, contains viral and cellular proteins, as well as viral RNA
and DNA (33). Fraction 5, which had a density of 1.32 g/ml, cor-
responded to the fraction containing RTCs and also had peak viral
sssDNA, as determined by qPCR (3, 28, 33, 34). No viral DNA
was detected in gradient fractions using heat-inactivated HIV-1
(data not shown), as reported previously (3). Nullbasic-treated
HIV-1 produced 3-fold less viral DNA than untreated HIV-1,
which is consistent with but slightly lower than defects we re-
ported previously (10, 14). This is most likely due to levels Null-
basic expression plasmid used here at minimal levels sufficient to
observe defects in infectivity. Although the distribution of sss-
DNA was observed in fractions 1 to 8, Nullbasic-treated HIV-1
had 36% of the total viral sssDNA in fraction 5 compared to
56% for untreated HIV-1. Analysis of CA in each fraction showed
that untreated virus had a clear peak amount in fraction 5 (Fig.
6B). However, HIV-1 containing Nullbasic had a majority of CA
in fractions with lower densities (fractions 6 to 8). The data sug-
FIG 4 Nullbasic is present in HIV-1 virions. (A) HEK293T cells were transfected with a Nullbasic-FLAG-mCherry expression plasmid. After 24 h, the cells were
stained with DAPI. The cells were visualized by fluorescent confocal microscopy, and the white bar in the left panel indicates 10 m. (B) Isolation of HIV-1 by
velocity gradient centrifugation and detection of Nullbasic. HIV-1 was produced by cotransfection of a proviral plasmid with a Nullbasic-FLAG expression
plasmid (right panel) or an empty expression plasmid (left panel). The virus was pelleted through 20% sucrose cushion, collected in 1 PBS, placed on the top
of a linear 6 to 18% iodixanol gradient, and centrifuged for 1.5 h at 250,000 g. Fractions were collected from the top and were assayed for CAp24 by ELISA and
Nullbasic-FLAG byWestern blot analysis with an anti-FLAG antibody. The experiment was repeated three times with similar results. The results of a represen-
tative experiment are shown.
FIG 5 Subtilisin digestion of HIV-1 indicates Nullbasic is packaged in virions.
HIV-1 virus stocks described used for velocity gradient analysis were pelleted
through a 20% sucrose cushion. Samples of each concentrated virus were
incubated with or without 1 subtilisin digestion buffer and analyzed by
Western blot analysis. (A) Concentrated HIV-1 produced in the absence (lane
1) or presence (lane 2) of Nullbasic underwent Western blot analysis with an
anti-HIV antibody (top panel) or theM2 anti-FLAG antibody (bottompanel).
(B) Western blot analysis of Nullbasic-treated HIV-1 with antibodies specific
for gp120 (top panel), CA (second panel), MA (third panel), and FLAG (that
detects Nullbasic) in the presence or absence of subtilisin as indicated. (C) A
Western blot as described for panel B but using HIV-1 made by cells not
coexpressing Nullbasic. The experiment was repeated twice with similar re-
sults, and the results of a representative experiment are shown.
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gest that the redistribution of viral DNA and CA to non-RTC
fractions is due to a Nullbasic-induced change in the composition
or organization of RTCs or increased uncoating.
HIV-1 in vitro core disassembly is increased by Nullbasic.
The efficiency and timing of HIV-1 reverse transcription can be
affected by stability of the viral core (35, 36). For example, HIV-1
having point mutations in CA can have increased or decreased
core stability and which have reduced reverse transcription effi-
ciency in cells. The possibility that Nullbasic affected core archi-
tecture was assessed by thin-section electron microscopy (Fig. 7).
The results show thatmost virus particles produced without Null-
basic had a mature morphology with an intact viral core (60%).
Virus particles produced in the presence of Nullbasic showed a
slight but not statistically significant reduction in levels virions
with mature morphology (54%) and a commensurate increase in
virionswith an immaturemorphology. AWestern blot of the virus
producing cells confirmed the expression of Nullbasic-FLAG, as
expected (Fig. 7C). The disassembly of virion cores was measured
using a in vitro uncoating assay (30), with cores purified from
HIV-1 and Nullbasic-containing HIV-1. Samples containing
equivalent amounts cores from sucrose gradient fractions were
incubated at either 4 or 37°C for 0, 60, or 120 min. The samples
underwent ultracentrifugation to sediment intact cores, leaving
CA from disassembled cores in the supernatant. As shown in Fig.
8, Western blotting of pelleted cores with an anti-CA antibody
consistently showed decreased amounts of CA in pelleted cores
isolated from Nullbasic-treated HIV-1 at 120 min compared to
untreated HIV-1 cores. The results obtained here, combined with
analysis of the CA content in RTC fractions, indicate that Nullba-
sic incorporation can lead to accelerated core uncoating in vitro.
Nullbasic does not affect viral entry of VSV-G-pseudotyped
HIV-1. We previously showed that Nullbasic has no effect on
entry of lentiviral particles pseudotyped with VSV-G envelope
(14). The disruption of entry of pseudotyped HIV-1 in HEK293T
cells was tested (Fig. 9). The experiment can detect viral genomic
RNA postinfection as an indicator of viral entry. HEK293T cells
were treated with 1MNVP for 2 h and then incubated with each
HIV-1 sample at 4°C for 2 h. A heat-inactivated sample of each
HIV-1 was used as a negative control. NVP was used to block
reverse transcription and degradation of viral genomic RNA by
RT RNase H activity. The cells were incubated at 37°C for 2 h to
permit viral entry, and the total cellular RNA was collected. RT-
PCR was used to measure the levels of viral genomic RNA that
were normalized to levels of cellular eEF1AmRNA in each sample.
The results show that similar levels of viral genomic RNA were
detected irrespective of the presence of absence of Nullbasic in
virus particles.
DISCUSSION
Our previous studies showed that HIV-1 or HIV-1-based lentivi-
ral virus-like particles produced by cells expressing Nullbasic are
defective for synthesis of sssDNA by 4- to 10-fold in a dose-
dependent manner (10, 14). The experiments described here sup-
port a model in which a direct interaction between Nullbasic and
RT leads to defective core disassembly and reverse transcription.
First, coexpression ofNullbasic andHIV-1 in cells results in virion
containing Nullbasic. Second, co-IP and pulldown assays indicate
interaction between Nullbasic and RT, and BLI assays indicated a
direct interaction. Incorporation of Nullbasic by HIV-1 leads to
accelerated core disassembly and defective reverse transcription
postinfection. This is supported by in vitro uncoating assays, by
reduced amounts of viral cDNA in RTC fractions, and by in-
creased redistribution of CA into non-RTC fractions. In sharp
contrast, we observed no inhibition of RT activity by recombinant
Nullbasic in a standard homopolymer RT assay even when added
at a 20,000-fold molar excess compared to RT. Given the out-
comes reported here and the observation that Nullbasic can in-
hibit sssDNA synthesis in endogenous and cell-based reverse
transcription assays (10, 14), we propose that Nullbasic inhibits
reverse transcription by disrupting assembly of the prototypical
RTC in virions, rather than by directly inhibiting RT activity, and
this results in accelerated uncoating and fewer functional RTC
following cell infection. To our knowledge, only one other antivi-
ral molecule, amethylated oligoribonucleotide, targeting the RTC
has been reported (37).
We showed that Nullbasic can bind RT and affects core stabil-
ity in vitro and activity of RTCs in cells. It is possible that interac-
FIG6 Inhibition of RTCDNA synthesis byNullbasic. HIV-1was produced by
cotransfection of a proviral plasmid with a Nullbasic-FLAG expression plas-
mid () or an empty expression plasmid () as described in Materials and
Methods. HEK293T cells were infected with VSV-G-pseudotyped HIV-1. Cell
lysates were prepared 4 h postinfection and layered on top of a 20 to 70% linear
sucrose gradient. After centrifugation, fractions were collected from the bot-
tom and the density of each fraction was measured (dashed line). A sample
from each fraction was assayed for HIV-1sssDNA by qPCR (top graph) and
for CAp24 by ELISA (bottom graph). The experiment was repeated twice with
similar results, and the results of a representative experiment are shown.
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tion between RT and Nullbasic affects other RTC components.
Matrix, CA, nucleocapsid, Vpr, Vif, and integrase have been de-
tected in the partially purified RTC (33, 34, 38, 39), and roles of
each RTC component in early virus replication have been dis-
cussed in detail elsewhere (1). The present study shows that Null-
basic may can be a useful tool for investigation on the biology of
uncoating, RTC activity that may reveal novel antiviral strategies
to target the RTC.
FIG 7 Effect of Nullbasic on virion morphology. (A) Representative electron micrograph images illustrating mature, eccentric, and immature particle mor-
phologies. (B) Frequencies of the different core morphologies for HIV-1 produced by HEK293T cells transfected with pGCH proviral plasmid and pcDNA3.1-
FLAG (black bars) or pcDNA3.1-Nullbasic-FLAG (gray bars). Mean values and standard errors of the mean were determined by comparing three independent
sets of 60 to 180 virus particles each. Statistical analysis was performed using a Student t test from at least three independent measurements. The statistical
significance was set at P 0.05. (C) Western blot of lysates from the transfected cells using anti-capsid, anti-FLAG, or anti-tubulin antibodies.
FIG 8 Nullbasic incorporation in HIV-1 leads to increased core disassembly
kinetics in vitro. Purified cores from HIV-1 or HIV-1 containing Nullbasic
were incubated at 4 or 37°C for 0, 60, or 120 min. (A)Western blot analysis of
treated cores. The treated samples underwent ultracentrifugation, and the pro-
tein sediment was solubilized in an SDS–2% PAGE loading dye and analyzed
by Western blotting with a monoclonal anti-CA antibody and a secondary
antibody conjugated to HRP. The blots were developed using chemilumines-
cence. (B)Disassembly kinetics of viral cores in vitro at 37°C. Quantification of
the protein bands from all experiments was calculated using digital images and
ImageJ software. The percent disassembly was calculated by comparing values
at 60 and 120 min to those at time zero. The results show mean values and
standard errors of themean. The experiment was repeated three times, and the
results of a representative result are shown.
FIG 9 Entry of VSV-G-pseudotyped HIV-1 is not affected by Nullbasic.
HEK293 cells were treated with 1Mnevirapine (to prevent reverse transcrip-
tion and degradation of viral mRNA by RNase H activity) for 2 h at 37°C and
then incubated with VSV-G-pseudotyped HIV-1 or HIV-1-Nullbasic viral su-
pernatant containing 500 ng of CA for 2 h at 4°C to facilitate virus attachment.
Heat-treated virus was used as a control for attachment and entry. The cells
were incubated at 37°C to initiate envelope and cell membrane fusion, fol-
lowed by incubation for a further 2 h. Total cellular RNA was collected and
analyzed by RT-PCR for HIV-1 full-length mRNA and cellular eEF1A mRNA
in the presence or absence of RT. The relative copy number of HIV-1 RNAwas
normalized to levels of eEF1AmRNA in each sample. A negative control with-
out cDNA template was included in every assay. All PCRs were performed in
triplicate. The experiment was performed twice with similar results. The re-
sults of a representative experiment are shown. NB and NB, the absence
and presence of Nullbasic, respectively.
Lin et al.
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Tat is a virion protein (13) that has reported paradoxical abil-
ities to positively (7, 8, 11, 12, 40–43) or negatively (9, 44, 45)
affect DNA synthesis by, ormolecular components important for,
reverse transcription. The opposing effects of Tat on reverse tran-
scription leave open possibilities that Nullbasic may be either a
TDNi form of Tat or a better Tat-based inhibitor of reverse tran-
scription. Some observations and further experimentsmay help to
resolve the issue. First, our experience is that inclusion of the basic
domain greatly increases steady-state levels of Nullbasic com-
pared to Tat (unpublished observation). Since Nullbasic down-
regulates reverse transcription in a dose-dependent manner (10),
increased steady-state levels of Nullbasic in the cells may enhance
the concentrations of Nullbasic and hence its antiviral effects. Sec-
ond, the basic domain of Tat is capable of direct interaction with
the TAR RNA stem-loop structure (46–48), which is formed by
viral genomic RNA (49) and has been implicated as important for
the nucleic acid annealing activity of Tat (9, 41–43, 50, 51). One
possibility is that Tat binding to RT and its RNA annealing activ-
ities help to coordinate RTC assembly, which is disrupted by the
basic domain mutation in Nullbasic. This scenario shares ele-
ments of the mechanism attributed to Tat TDN mutants, which
can bind pTEFb but are unable to direct pTEFb to TAR RNA for
efficient transcription (20). Structural studies of the viral RNA/
tRNAlys3 RNA complex in the presence of RT or the RT-Nullba-
sic complex (49, 52) should help to further clarify a role for Tat in
sssDNA synthesis. In addition, analysis of point mutants in
Nullbasic should identify a domain(s) required for interaction
withRT andmay determine the relative importance of RTbinding
and RNA annealing functions of Tat in reverse transcription.
The complexity of abundant interactions between Tat and
other viral and cellular proteins are well known (53). Although
Nullbasic has potential as an antiviral agent by inhibiting three
steps of HIV replication, possibly using a gene therapy approach,
it also has utility as a probe to investigate fundamental mecha-
nisms that underlie interaction between HIV proteins.
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